The systemic amyloidosis therapeutic market is gaining significant momentum driven by advancements in targeted therapies and growing diagnosis rates worldwide. Increasing investment in innovative treatment options is shaping the industry landscape, setting the stage for robust business growth and evolving market dynamics from 2026 onwards.


Market Size and Overview
The Global Systemic Amyloidosis Therapeutic Market is estimated to be valued at USD 6.69 Bn in 2025 and is expected to reach USD 11.54 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8.1% from 2025 to 2032.

This market forecast underscores rapid market revenue expansion propelled by increasing patient awareness and enhanced therapeutic pipelines. The expanding industry size reflects a rising Systemic Amyloidosis Therapeutic Market Scope demand for improved treatment modalities addressing amyloidosis-related complications, thereby highlighting vital market opportunities amid escalating market challenges.

Market Segments
The market analysis identifies three core systemic amyloidosis therapeutic market segments:

- Therapeutic Type: Dominated by novel RNA interference therapies, with antisense oligonucleotides as the fastest-growing sub-segment, exemplified by Ionis Pharmaceuticals' recent launches in 2024 targeting transthyretin amyloidosis.
- Disease Type: Light chain (AL) amyloidosis retains dominance due to higher prevalence, while transthyretin (ATTR) amyloidosis constitutes the fastest-growing segment, driven by demographic shifts and enhanced diagnostic techniques.
- End User: Hospitals continue to be the dominant care delivery channel, whereas specialized amyloidosis treatment centers are rapidly expanding, capitalizing on customized therapies and precision medicine approaches.

‣ Get more insights on : Systemic Amyloidosis Therapeutic Market

‣ Get this Report in Japanese Language:   全身性アミロイドーシス治療市場

‣ Get this Report in Korean Language:   전신성아밀로이드증치료시장